David Swoboda, MD, Talks MDS Highlights at ASH 2023

Dr. Swoboda, Director of Leukemia at Tampa General Hospital in Florida, talks highlights on myelodysplastic syndromes (MDS) from the 65th American Society of Hematology Annual Meeting & Exposition.

“We’ve had a great year in MDS with two pivotal phase III studies presented at ASCO, the first being the COMMANDS study with luspatercept,” he said. “This was a frontline study [that was] extremely practice-changing for a lot of clinicians and researchers.”

He added the other trial was the phase III IMerge trial, the randomized, double-blind, placebo-controlled study evaluated imetelstat in patients with heavily transfusion dependent non-del(5q) lower-risk MDS who relapsed or were refractory to erythropoiesis stimulating agents.